This inventor holds 1 USPTO granted patent and 5 published patent applications and 1 EPO patent. Top assignee: Novartis Ag. Active years: 2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2025
Title: Hyungwook Lim: Innovator in Chimeric Antigen Receptors
Introduction
Hyungwook Lim is a prominent inventor based in Cambridge, MA (US). He has made significant contributions to the field of immunotherapy, particularly through his work on chimeric antigen receptors (CARs). His innovative approach has the potential to enhance the effectiveness of immune effector cells in targeting cancer.
Latest Patents
Hyungwook Lim holds a patent for "Chimeric antigen receptors and uses thereof." This invention provides immune effector cells, such as T cells and NK cells, that express a chimeric antigen receptor. The patent outlines various compositions and methods for utilizing these cells in therapeutic applications.
Career Highlights
Lim is currently associated with Novartis AG, a leading global healthcare company. His work at Novartis focuses on advancing the development of CAR technology to improve cancer treatment options. His expertise in this area has positioned him as a key player in the field of immunotherapy.
Collaborations
Hyungwook Lim collaborates with notable colleagues, including Aida Abujoub and John Blankenship. These partnerships enhance the research and development efforts in the field of chimeric antigen receptors.
Conclusion
Hyungwook Lim's contributions to the development of chimeric antigen receptors represent a significant advancement in cancer immunotherapy. His innovative work continues to pave the way for new therapeutic strategies that could improve patient outcomes.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile